Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial

被引:4
作者
Williams, Hannah [1 ]
Yuval, Jonathan B. [1 ,2 ]
Verheij, Floris S. [1 ]
Miranda, Joao [3 ]
Lin, Sabrina T. [4 ]
Omer, Dana M. [1 ]
Qin, Li-Xuan [4 ]
Gollub, Marc J. [3 ]
Kim, Tae-Hyung [3 ]
Garcia-Aguilar, Julio [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Colorectal Serv, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Tel Aviv Sourasky Med Ctr, Dept Surg, Tel Aviv, Israel
[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
关键词
TOTAL MESORECTAL EXCISION; OPEN-LABEL; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; TUMOR RESPONSE; CANCER; SURVIVAL; CHEMORADIATION; THERAPY;
D O I
10.1093/bjs/znae246
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Prospective randomized trials have not yet identified baseline features predictive of organ preservation in locally advanced rectal cancers treated with total neoadjuvant therapy and a selective watch-and-wait strategy.Methods This was a secondary analysis of the OPRA trial, which randomized patients with stage II-III rectal adenocarcinoma to receive either induction or consolidation total neoadjuvant therapy. Patients were recommended for total mesorectal excision, or watch and wait based on clinical response at 8 +/- 4 weeks after completing treatment. Standardized baseline clinical and radiological variables were collected prospectively. Survival outcomes, including total mesorectal excision-free survival, disease-free survival, and overall survival, were assessed by intention-to-treat analysis. Cox proportional hazards models were used to evaluate associations between baseline variables and survival outcomes.Results Of the 324 patients randomized for the OPRA trial, 38 (11.7%) had cT4 tumours, 230 (71.0%) cN-positive disease, 101 (32.5%) mesorectal fascia involvement, and 64 (19.8%) extramural venous invasion. Several baseline features were independently associated with recommendation for total mesorectal excision on multivariable analysis: nodal disease (HR 1.66, 95% c.i. 1.12 to 2.48), extramural venous invasion (HR 1.57, 1.07 to 2.29), mesorectal fascia involvement (HR 1.45, 1.01 to 2.09), and tumour length (HR 1.11, 1.00 to 1.22). Of these, nodal disease (HR 2.02, 1.15 to 3.53) and mesorectal fascia involvement (HR 2.02, 1.26 to 3.26) also predicted worse disease-free survival. Age (HR 1.03, 1.00 to 1.06) was associated with overall survival.Conclusion Baseline MRI features, including nodal disease, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict the likelihood of organ preservation after completion of total neoadjuvant therapy. Mesorectal fascia involvement and nodal disease are associated with disease-free survival. Prospective randomized studies have not yet evaluated baseline features that predict organ preservation in locally advanced rectal cancer treated with total neoadjuvant therapy and a selective watch-and-wait strategy. This secondary analysis of the OPRA trial demonstrated that baseline MRI features, including nodal status, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict total mesorectal excision-free survival. Nodal status and mesorectal fascia involvement are associated with disease-free survival.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Organ Preservation in the Treatment of Stage II and III Rectal Cancer
    Hagen, Edward R.
    Cleary, Robert K.
    [J]. DISEASES OF THE COLON & RECTUM, 2020, 63 (09) : 1185 - 1189
  • [32] Total neoadjuvant therapy for organ preservation in patients with rectal cancer
    Siegel, R.
    [J]. COLOPROCTOLOGY, 2022, 44 (04) : 273 - 276
  • [33] Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival
    Kim, Jin K.
    Thompson, Hannah
    Jimenez-Rodriguez, Rosa M.
    Wu, Fan
    Sanchez-Vega, Francisco
    Nash, Garrett M.
    Guillem, Jose G.
    Paty, Philip B.
    Wei, Iris H.
    Pappou, Emmanouil P.
    Widmar, Maria
    Weiser, Martin R.
    Smith, J. Joshua
    Garcia-Aguilar, Julio
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (02) : 1172 - 1179
  • [34] TNT for organ preservation in rectal cancer: still looking for the right schedule and patient
    Grotenhuis, B. A.
    Couwenberg, A. M.
    Marijnen, C. A. M.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (11) : 928 - 929
  • [35] Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
    Yoo, Ri Na
    Kim, Hyung Jin
    [J]. ANNALS OF COLOPROCTOLOGY, 2019, 35 (02) : 53 - 64
  • [36] Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation
    Albert M. Wolthuis
    Freddy Penninckx
    Karin Haustermans
    Nadine Ectors
    Eric Van Cutsem
    André D’Hoore
    [J]. Annals of Surgical Oncology, 2011, 18 : 684 - 690
  • [37] Organ preservation by chemoradiation for bladder cancer
    Durdux, C.
    Fabiano, E.
    Mejean, A.
    [J]. CANCER RADIOTHERAPIE, 2019, 23 (6-7): : 732 - 736
  • [38] Advances in Organ Preservation for Laryngeal Cancer
    Campbell, Graham
    Glazer, Tiffany A.
    Kimple, Randall J.
    Bruce, Justine Yang
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (04) : 594 - 608
  • [39] Total glossectomy in the organ preservation era
    Vartanian, Jose G.
    Magrin, Jose
    Kowalski, Luiz P.
    [J]. CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2010, 18 (02) : 95 - 100
  • [40] A nomogram predicting pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: implications for organ preservation strategies
    Sun, Yanwu
    Chi, Pan
    Lin, Huiming
    Lu, Xingrong
    Huang, Ying
    Xu, Zongbin
    Huang, Shenghui
    Wang, Xiaojie
    [J]. ONCOTARGET, 2017, 8 (40) : 67732 - 67743